Oncimmune expands access to cancer risk lung, liver blood tests

Oncimmune Holdings entered into an agreement with America’s Choice Provider Network to expand access to the company’s EarlyCDT-Lung and EarlyCDT-Liver blood tests, designed to assess cancer risks, according to a press release.

“Our collaboration with America’s Choice Provider Network is one of several payor and provider agreements we have recently finalized to ensure as many people as possible in the U.S. are able to use our EarlyCDT tests to facilitate earlier diagnoses,” Marco Casarin, general manager of Oncimmune, said in the release.

According to the release, EarlyCDT-Liver aids in the detection and confirmation of hepatocellular carcinoma in association with imaging for patients who are considered high-risk with liver lesions of varying size.

EarlyCDT-Lung has been used previously to assess lung cancer risk in high-risk patients with indeterminate pulmonary nodule, providing a supplement to computed tomography scanning.

Oncimmune’s EarlyCDT technology launched in 2009.

“Especially in lung cancer ... a positive EarlyCDT-Lung outcome enables quicker clinician intervention and better patient outcomes,” Casarin noted in the release.”

Reference: www.oncimmune.com